Article Text

Download PDFPDF
Dabigatran associated with increased risk of acute coronary events
  1. Payal Kohli1,
  2. Christopher Paul Cannon2
  1. 1Division of Cardiology, University of California San Francisco, San Francisco, California, USA
  2. 2TIMI Study Group/Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA
  1. Correspondence to: Christopher Paul Cannon
    TIMI Study Group/Cardiovascular Division, Brigham and Women's Hospital, 350 Longwood Avenue, 1st floor office, Boston, MA 02115, USA; cpcannon{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMedWeb of Science


The novel oral anticoagulants, comprised of direct thrombin inhibitors (DTIs) (ie, dabigatran) and the factor Xa inhibitors (ie, rivaroxaban, apixaban and edoxaban), are revolutionising the way patients are anticoagulated. Recent years have witnessed a surge of trials evaluating these drugs in many clinical contexts. However, with such rapid uptake, it becomes critical to carefully evaluate safety data in order to optimise patient selection and minimise risk.

The largest of the contemporary trials with dabigratran, the Randomised Evaluation of Long-term Anticoagulation (RE-LY), randomised 18 113 patients with …

View Full Text